UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000055552
Receipt number R000063484
Scientific Title Observational Study for the Prognosis and diagnostic accuracy of Triglycerides Deposit Cardiomyovasculopathy
Date of disclosure of the study information 2024/09/20
Last modified on 2024/09/20 00:42:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational Study for the Prognosis and diagnostic accuracy of Triglycerides Deposit Cardiomyovasculopathy

Acronym

Observational Study for Triglycerides Deposit Cardiomyovasculopathy

Scientific Title

Observational Study for the Prognosis and diagnostic accuracy of Triglycerides Deposit Cardiomyovasculopathy

Scientific Title:Acronym

Observational Study for Triglycerides Deposit Cardiomyovasculopathy

Region

Japan


Condition

Condition

Triglyceride deposit cardiomyovasculopathy

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of the study is to elucidate the relationship between various diagnostic testing, clinical findings, and disease prognosis in triglyceride deposit cardiomyovasculopathy. Another purpose of the study include clarifying the correlation between pathological findings that can substantiate a definitive diagnosis and various imaging modalities that assist in diagnosis, aiming to improve diagnostic accuracy.

Basic objectives2

Others

Basic objectives -Others

Evaluate the usefulness of unestablished diagnostic methods in comparison with existing diagnostic criteria for the diagnosis of triglyceride deposit cardiomyovasculopathy

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Composite endpoint including lethal arrhythmia, heart failure hospitalization, cardiovascular death, and all-cause mortality

Key secondary outcomes

Arrhythmic events including bradycardia, supraventricular tachycardia, and ventricular tachycardia
Heart failure hospitalization
Any hospitalization for the cardiovascular management, excluding heart failure
Cardiovascular death
All-cause mortality


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient providing written informed consent

Key exclusion criteria

not applicable

Target sample size

250


Research contact person

Name of lead principal investigator

1st name Kenichiro
Middle name
Last name Suwa

Organization

Hamamatsu University School of Medicine

Division name

Internal Medicine III, Division of Cardiology

Zip code

431-3192

Address

1-20-1 Handayama Chuou-ku, Hamamatsu

TEL

0534352267

Email

k-suwa@hama-med.ac.jp


Public contact

Name of contact person

1st name Kenichiro
Middle name
Last name Suwa

Organization

Hamamatsu University School of Medicine

Division name

Internal Medicine III, Division of Cardiology

Zip code

431-3192

Address

1-20-1 Handayama Chuou-ku, Hamamatsu

TEL

0534352267

Homepage URL


Email

k-suwa@hama-med.ac.jp


Sponsor or person

Institute

Hamamatsu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Hamamatsu University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hamamatsu University School of Medicine

Address

1-20-1 Handayama Chuou-ku, Hamamatsu

Tel

0534352194

Email

kenkyou.k@hama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 09 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 12 Month 19 Day

Date of IRB

2024 Year 02 Month 13 Day

Anticipated trial start date

2024 Year 02 Month 13 Day

Last follow-up date

2028 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study targets patients in whom triglyceride deposit cardiomyovasculopathy (TGCV) is a differential diagnosis and who are scheduled to undergo I-123 BMIPP scintigraphy. Using current diagnostic criteria, patients will be classified into TGCV and non-TGCV groups. Observational parameters include cardiac MRI (cine, strain, late gadolinium enhancement, T1 mapping, T2 mapping, MR spectroscopy), cardiac CT (coronary artery evaluation, myocardial fat deposition assessment), 99mTc-MIBI resting myocardial scintigraphy (including washout rate), and I-123 BMIPP (including washout rate and dynamic SPECT). The study aims to clarify the relationship between these parameters and the composite endpoint, the primary outcome measure (lethal arrhythmia, heart failure hospitalization, cardiovascular death, all-cause mortality).


Management information

Registered date

2024 Year 09 Month 20 Day

Last modified on

2024 Year 09 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063484